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Abstract
 
Plasmacytoid dendritic cells (pDCs) have been identified as a potent secretor of the type I in-
terferons (IFNs) in response to CpG as well as several viruses. In this study, we examined the
molecular mechanism of virus recognition by pDCs. First, we demonstrated that the
CD11c
 
 
 
Gr-1
 
int
 
B220
 
 
 
 pDCs from mouse bone marrow secreted high levels of IFN-
 
 
 
 in re-
sponse to either live or UV-inactivated Herpes simplex virus-2 (HSV-2). Next, we identified
that IFN-
 
 
 
 secretion by pDCs required the expression of the adaptor molecule MyD88, sug-
gesting the involvement of a Toll-like receptor (TLR) in HSV-2 recognition. To test whether
a TLR mediates HSV-2–induced IFN-
 
 
 
 secretion from pDCs, various knockout mice were
examined. These experiments revealed a clear requirement for TLR9 in this process. Further,
we demonstrated that purified HSV-2 DNA can trigger IFN-
 
 
 
 secretion from pDCs and that
inhibitory CpG oligonucleotide treatment diminished HSV-induced IFN-
 
 
 
 secretion by pDCs
in a dose-dependent manner. The recognition of HSV-2 by TLR9 was mediated through an
endocytic pathway that was inhibited by chloroquine or bafilomycin A1. The strict require-
ment for TLR9 in IFN-
 
 
 
 secretion was further confirmed by the inoculation of HSV-2 in
vivo. Therefore, these results demonstrate a novel mechanism whereby the genomic DNA of a
virus can engage TLR9 and result in the secretion of IFN-
 
 
 
 by pDCs.
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Introduction
 
Herpes simplex virus-2 (HSV-2) is one of the most com-
mon sexually transmitted diseases with a high prevalence of
45 million in the USA (1). HSV-2 is primarily transmitted
via exposure at the genital mucosal surfaces, which leads to
the establishment of latency in the sacral ganglia. Although
pharmacological interventions are used for the treatment of
HSV-2–related symptoms, there are no preventative vac-
cines or curative measures available for this disease. Toward
developing vaccines to prevent HSV-2 transmission, a clear
understanding of the mechanism of how immunity is gen-
erated within the relevant mucosal sites is necessary.
DCs are the most potent APCs found throughout the
body, particularly at the sites of potential encounter with
pathogens such as the mucosal surfaces. In a recent study,
using an in vivo mouse model for genital herpes, we dem-
onstrated an essential role of DCs in Th1 induction follow-
ing HSV-2 infection in the vaginal mucosa (2). Specifically,
CD11b
 
 
 
 DCs were found to present virus antigens to
CD4
 
 
 
 T cells in the draining lymph nodes, and this interac-
tion was crucial in the generation of the potent Th1 response
(2) needed to provide protective immunity. Consistent with
the ability of these cells to induce T cell activation, the
DCs in the draining lymph nodes were found to increase
their levels of costimulatory molecules as early as 24 h after
intravaginal infection with HSV-2 (2). One of the major
pathways of DC activation involves the recognition of con-
served molecules found on microbes via the Toll-like re-
ceptors (TLRs). Although the TLRs have been shown to
play a crucial role in the innate recognition of bacterial and
fungal pathogens (3), the role of TLRs in antiviral immu-
nity in vivo is unclear.
Of the number of DC subtypes identified in recent years,
the plasmacytoid DC (pDC) is characterized for its potent
ability to secrete type I interferons in response to viruses
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(4–7). The phenotype of these type I IFN producing pDCs
has been found to differ by species, as they are CD4
 
 
 
CD11c
 
 
 
 in humans (8) but in mice have been identified as
CD11c
 
 
 
CD11b
 
 
 
Gr-1
 
 
 
B220
 
 
 
 cells (4, 9). Whereas DCs as
a class are thought to be the professional antigen presenting
cells specializing in antigen uptake, processing, and presen-
tation to T cells, the predominant role of the pDCs appears
to be the secretion of type I IFNs. In particular, pDCs can
be induced to secrete large amounts of IFN-
 
 
 
 when stim-
ulated with oligodeoxynucleotides containing certain CpG
motifs (5–7, 10) or viruses including sendai virus (7), influ-
enza (4), and HSV-1 (5, 6). However, this situation may
not be universal, as one study found that pDCs are the ma-
jor producers of IFN-
 
 
 
 and IFN-
 
 
 
 after murine cytomeg-
alovirus (MCMV), but not lymphocytic choriomeningitis
virus (LCMV), infections in vivo (11), thereby highlight-
ing a differing cell requirement for type I IFN responses
dependent on the type of viral stimulus. Type I IFNs have
an essential role in antiviral defense (12), mediated by
pathways involving PKR and 2
 
 
 
-5
 
 
 
 oligoadenylate syn-
thetase (13). Thus, pDCs serve an important role in
providing innate antiviral immunity early during virus
infection.
Although the ability of pDCs to secrete type I IFNs in
response to viruses has been well characterized, the signal-
ing events subsequent to viral infection that lead to type I
IFN secretion have not yet been elucidated. In humans,
pDCs, as compared with other subsets of DCs, express
high levels of TLR7 and TLR9 (7, 14). In mice, pDCs, as
well as other DC subsets, are found to express TLR9 (5,
15). The ligand for TLR9 has been identified as unmeth-
ylated CpG motifs found within microbial DNA se-
quences (16). Furthermore, it has been found that differ-
ent CpG sequences have distinct stimulatory capacities
and that certain DNA sequences can inhibit the stimula-
tory effects of CpG (17). Therefore, we hypothesized that
the TLR9 expressed on pDCs could bind to unmeth-
ylated CpG motifs present on HSV-2 genomic DNA,
thereby serving as the receptor responsible for secretion of
type I IFNs by pDCs. Unlike small viruses, the HSV ge-
nome contains a high frequency of CpG motifs (18)
which have been shown to have significant functional ac-
tivity in vivo (19).
In this study, we describe a molecular mechanism of
HSV-2 recognition by pDCs. We provide evidence that
the ability of the pDCs to recognize and secrete IFN-
 
 
 
 in
response to HSV-2 required TLR9 expression by pDCs.
The recognition of the virus does not require replication
since live and UV-inactivated HSV-2 induced identical
IFN-
 
 
 
 secretion from pDCs. Further, we demonstrated
that the ligand recognized by TLR9 is likely the genomic
DNA of HSV-2. In vivo, the ability of HSV-2 to stimu-
late IFN-
 
 
 
 secretion depended on the functional expres-
sion of TLR9. These results represent the first evidence
for the requirement of TLR9 signaling in the generation
of antiviral immunity, and suggest the importance of
TLR9 mediated recognition of other DNA viruses in
vivo.
 
Materials and Methods
 
Viruses and Viral DNA Isolation.
 
HSV-2 strain (186TK
 
 
 
Kpn)
(20) and HSV-1 strain (KOS) were provided by Dr. David Knipe
(Harvard University Medical School, Boston, MA) and were
propagated and assayed on Vero cells. Briefly, confluent Vero
cells were infected with HSV strains at a multiplicity of infection
(MOI) of 0.005 and incubated with virus for 1 h at 37
 
 
 
C. Super-
natant containing the virus was removed and cells were incu-
bated at 37
 
 
 
C until complete infection had occurred (2–3 d) in
the presence of DMEM with 1% FBS. Cells were centrifuged at
1,500 rpm for 5 min and supernatant was collected and saved.
Cells were resuspended in a 1:1 mixture of sterile autoclaved
milk and supernatant and frozen overnight at 
 
 
 
80
 
 
 
C. Virus was
thawed and sonicated, and the sonicated material was clarified by
centrifugation at 1,600 rpm for 10 min at 4
 
 
 
C. Pure viral stocks
were prepared by a similar method. Briefly, confluent Vero cells
were infected as above and after a 2–3 d incubation, cells were
centrifuged as described and the cell pellet was discarded. The
supernatant was ultracentrifuged at 20,000 
 
g
 
 at 15
 
 
 
C for 45 min.
The pellet was resuspended in sterile PBS and stored at 
 
 
 
80
 
 
 
C.
All virus stocks were titered on the Vero cell line before use. In
some cases, the purified virus was UV-inactivated by exposure to
1 J/cm
 
2
 
 UV light with a Stratalinker
 
®
 
 UV Cross-linker (Strat-
agene) as described previously (21). To obtain HSV-2 genomic
DNA, QIAamp DNA Mini Kit (QIAGEN) was used to isolate
viral DNA from purified HSV-2 according to the manufacturer’s
instruction for Blood and Body Fluid Spin Protocol. The con-
centration of the resultant purified genomic DNA was deter-
mined by spectrophotometric reading of the optical density at
260 nm and the quality of DNA was assessed by agarose gel elec-
trophoresis.
 
Animals.
 
6- to 8-wk-old male and female B6 129F2 mice
were obtained from The Jackson Laboratory. MyD88
 
 
 
/
 
 
 
 (22),
TLR4
 
 
 
/
 
 
 
 (23), and TLR9
 
 
 
/
 
 
 
 (16) mice (all on the B6 129F2
background) were previously described. Mice received i.v. tail
vein injections of UV-inactivated HSV-2 (10
 
7
 
 PFU/mouse) in
200 
 
 
 
l volumes while restrained. All procedures used in this study
complied with federal guidelines and institutional policies by the
Yale Animal Care and Use Committee.
 
Antibodies.
 
The following antibodies were used for the iden-
tification of pDCs and other cell types: anti-CD11c (HL3), anti-
CD11b (M1/70), anti-Ly-6G (Gr-1) (RB6–8C5), and anti-B220
(RA3–6B2), all purchased from BD Biosciences.
 
Bone Marrow Cell Preparation and Purification.
 
Bone marrow
cells were prepared from the femurs and tibiae of mice. A single
cell suspension was prepared and red blood cells were lysed. Total
bone marrow populations were stimulated in the presence of the
indicated reagents in 96-well, round-bottomed tissue culture
plates at 10
 
6
 
 cells in 200 
 
 
 
l of medium per well for 18 h. CD11c-
depleted, CD11b-depleted, or B220-depleted bone marrow cells
were prepared by negative selection using the LD-depletion col-
umns (Miltenyi Biotech) according to the manufacturer’s instruc-
tions. For FACS
 
®
 
 sorting of pDCs and nonpDCs, bone marrow
cells were stained with FITC-conjugated anti-CD11c, PE-conju-
gated anti-Gr-1, and CyChrome-conjugated anti-B220. Cells
were washed extensively and sorted using a FACSVantage™.
Sorted cells were incubated with various stimuli at 2 
 
 
 
 10
 
5
 
 cells
per well in 200 
 
 
 
l media. 18 h later, IFN-
 
 
 
 levels were measured
using ELISA.
 
In Vitro pDC Stimulation.
 
The following reagents were used
to stimulate cells in vitro: Poly I:C (Amersham Biosciences) at 25
 
 
 
g/ml, R-848 (InvivoGen) at 1 
 
 
 
g/ml, stimulatory CpG 2084
(TCCTGACGTTGAAGT), and inhibitory CpG 2088 (TCC-T
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TGGCGGGGAAGT; synthesized by Invitrogen) at various
concentrations as indicated. Both of these oligonucleotides had
the phosphodiester backbone. Purified HSV (live or UV-inacti-
vated) was added to pDCs at a final concentration of 5 
 
 
 
 10
 
6
 
PFU/ml. DNase treatment of genomic HSV-2 DNA was per-
formed at 37
 
 
 
C for 1 h using 312.5 Kunitz units/
 
 
 
l RNase-free
DNase (QIAGEN). To prevent endosome acidification, chloro-
quine or bafilomycin A1 (Sigma-Aldrich) was used before in vitro
stimulation. Briefly, bone marrow cells were preincubated with
0.01–0.001 mM chloroquine for 2 h or 10–500 nM bafilomycin
A1 for 30 min at 37
 
 
 
C before the addition of various stimulants.
Cells were then incubated for an additional 18 h at 37
 
 
 
C and cell
viability was confirmed by trypan blue exclusion assays. Superna-
tants were analyzed for cytokine production by ELISA.
 
ELISA Measurement of Murine IFN-
 
 
 
 and IL-12p40.
 
The lev-
els of mouse IFN-
 
 
 
 were determined by ELISA as described pre-
viously (11). Briefly, 96-well plates were coated with rat anti–
mouse IFN-
 
 
 
 (mAb F-18; HyCult Biotechnology) in carbonate
buffer overnight. Nonspecific binding was blocked and plates
were incubated with different concentrations of samples. Some
wells were incubated with known concentrations of recombinant
mouse IFN-
 
 
 
 standard in duplicate (HyCult Biotechnology). Af-
ter an overnight incubation, plates were sequentially incubated
with polyclonal rabbit anti–mouse IFN-
 
 
 
 (PBL Biomedical Lab-
oratories) for 1 h and with horseradish peroxidase-conjugated
donkey anti–rabbit F(ab
 
 
 
)
 
2
 
 (Jackson ImmunoResearch Laborato-
ries) for 1 h. Plates were developed using substrate solution TMB
(eBioscience) and the reaction was stopped with 2N H
 
2
 
SO
 
4
 
. Op-
tical density at 450 nm was measured and the concentration of
IFN-
 
 
 
 was calculated from the standard curve. The concentra-
tions of IL-12p40 from bone marrow cells stimulated with R848
were measured using the OptEIA kit (BD Biosciences) according
to manufacturer’s instructions.
 
Calculations of the Concentrations of the CpG Sequences.
 
These
calculations were based on the assumption that all CpG sequences
found in the HSV genome were immunologically active. Since
many of the CpG sequences in the HSV genome are highly stim-
ulatory, and others are non-stimulatory due to methylation (19),
this assumption approximately reflects the average of the total
functional stimulatory CpG content of the HSV genome. The
amount of total DNA present within a virion is calculated as fol-
lows: 1 PFU 
 
 
 
 1 virion which contains a genome of 154 kbp.
The average molecular weight of a nucleotide is 323 g/mol 5 
 
 
 
10
 
6
 
 PFU/ml contains 154 kbp 
 
 
 
 5 
 
 
 
 10
 
6
 
 
 
 
 
 7.7 
 
 
 
 10
 
11
 
 bp/ml 
 
 
 
1.54 
 
 
 
 10
 
12
 
 nucleotide/ml. 1.54 
 
 
 
 10
 
12
 
 nucleotide/ml 
 
 
 
 6.02 
 
 
 
10
 
23
 
 molecules (nucleotide)/mol 
 
 
 
 2.56 
 
 
 
 10
 
 
 
12 
 
mol/ml. 2.56 
 
 
 
10
 
 
 
12 
 
mol/ml 
 
 
 
 323 g/mol 
 
 
 
 8.26 
 
 
 
 10
 
 
 
10 
 
g/ml or 0.826 ng/
ml. Thus, the purified HSV-2 DNA, used at the concentration of
547.2 ng/ml, corresponded to roughly 600-fold higher levels
than that found in the virions at 5 
 
 
 
 10
 
6
 
 PFU/ml (547.2 ng/ml 
 
 
 
0.826 ng/ml 
 
 
 
 662.4 or roughly 600-fold).
The amount of immunostimulatory CpG oligonucleotide
needed to induce equivalent levels of IFN-
 
 
 
 in pDCs stimulated
with 5 
 
 
 
 10
 
6
 
 PFU/ml of HSV-2 was 5 
 
 
 
g/ml (see Fig. 2 A). The
amount of virus-associated DNA present in 5   106 PFU/ml is
0.826 ng/ml (see calculation above). Therefore, virion-associated
DNA was  6,000-fold more effective in IFN-  induction com-
pared with synthetic soluble CpG oligonucleotide.
The amount of iCpG required to completely block virus-
induced IFN-  was 100  g/ml. As the amount of virus-associ-
ated DNA present in 5   106 PFU/ml is 0.826 ng/ml, this
amount of iCpG represents 120,000-fold higher level compared
with the level of CpG motifs present in the HSV genome. As 10
 g/ml of iCpG was required to completely inhibit 100 ng/ml of
stimulatory CpG (see Fig. 3 A), or 100-fold, HSV-2–associated
DNA is 120,000   100   1,200 times more difficult to inhibit
than stimulatory CpG oligonucleotide.
Results
Bone Marrow Contains a High Frequency of pDCs That Se-
crete IFN-  upon HSV-2 Stimulation. We first examined
the distribution of the pDCs capable of secreting IFN- 
upon HSV-2 stimulation. Total lymph node, spleen, and
bone marrow cells were stimulated with HSV-2 in vitro,
and IFN-  levels were measured after 18 h. The lymph
node was found to contain very few cells capable of secret-
ing IFN-  in response to UV-inactivated HSV-2 (UV-
HSV-2) or Poly I:C stimulation, whereas the spleen and
bone marrow contained cells that secreted IFN-  (Fig. 1 A).
In particular, the bone marrow cells were found to se-
crete considerably higher levels of IFN-  in response to
Figure 1. Bone marrow contains a high frequency of pDCs that secrete
IFN- . (A) Total lymph node, spleen, and bone marrow cell suspensions
from B6 129F2 mice were cultured with either media alone, Poly I:C, or
UV-HSV-2, and IFN-  secretion was measured by ELISA. (B) Bone
marrow cells were analyzed by flow cytometry. CD11c  cells in gate R2
were examined for FSC vs. SSC as well as their expression of Gr-1 and
B220. (C) Total bone marrow cells depleted of either CD11c , CD11b ,
or B220  cells were stimulated for 18 h with either media alone, live
HSV-2 (5   106 PFU/ml), or UV-HSV-2 (5   106 PFU/ml). IFN-  was
detected by ELISA. (D) Total bone marrow cells were sorted into
CD11c B220  (pDC), CD11c B220 (B cells), and CD11c B220  frac-
tions and cultured with either media alone, live HSV-2 (5   106 PFU/
ml), UV-HSV-2 (5   106 PFU/ml), UV-HSV-1 (5   106 PFU/ml),
CpG (5  g/ml), or Poly I:C (25  g/ml) for 18 h. Cells were cultured at
106 cells/ml and IFN-  was measured by ELISA.T
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UV-HSV-2 than did splenic cells (Fig. 1 A). Next, the
presence of pDCs in the bone marrow was analyzed by
FACS®. The total bone marrow cell population was found
to contain  2.6% CD11c  cells (Fig. 1 B, left panel;
CD11c  cells   R2 gate), which displayed the characteris-
tic pDC phenotype, namely slightly larger than lympho-
cytes with a low granularity (Fig. 1 B, right panel). In addi-
tion, these cells were found to be B220  and expressed low
levels of CD11b (unpublished data) and varying levels of
Gr-1 (Fig. 1 B, center panel), also consistent with the pre-
viously described mouse pDC phenotype (4, 9, 10).
To determine the precise phenotype of cells capable of
secreting IFN-  in response to HSV-2 stimulus, bone
marrow cells were depleted of either CD11c , CD11b ,
or B220  cells using a magnetic depletion column and in-
cubated with live or UV-HSV-2. IFN-  secretion was
completely diminished in the population that was depleted
of CD11  or B220  cells (Fig. 1 C). CD11b-depleted
bone marrow cells were able to secrete levels of IFN- 
higher than an equivalent number of total bone marrow
cells, likely due to an  40% enrichment of pDCs caused
by the CD11b-depletion (Fig. 1 C, and unpublished data).
The complete block of IFN-  secretion in CD11c- or
B220-depleted bone marrow cells suggested that pDCs are
the cell type responsible for IFN-  secretion. To posi-
tively identify the phenotype of cells that secrete IFN- 
in the bone marrow, CD11c B220  cells, as well as
the  rest of the nonpDC bone marrow populations
(CD11c B220  and CD11c B220 ) were sorted by
FACS® and stimulated with HSV-2. The CD11c B220 
cells were the only sorted population capable of secreting
IFN-  in response to live or UV-HSV-2 (Fig. 1 D),
thereby identifying CD11c B220  pDCs as the IFN- 
producing cells in the bone marrow. An equivalent num-
ber of total (unsorted) bone marrow cells were also found
to secrete IFN- , albeit to a lesser extent, likely due to the
lower proportion of pDCs contained within total bone
marrow cells. Similar levels of IFN-  were secreted by the
sorted pDCs in response to live or UV-inactivated HSV-2,
indicating that virus replication was not required for this
stimulation (Fig. 1 D). Moreover, UV-inactivated HSV-2
and HSV-1 elicited similar levels of IFN-  secretion from
pDCs (Fig. 1 D). These pDCs also secreted IFN-  in re-
sponse to CpG (Fig. 1 D), suggesting that they express
functional TLR9.
MyD88 Is Required for HSV-2–induced IFN-  Secretion
from pDCs. To determine if a toll-like receptor is in-
volved in the recognition of HSV-2 by pDCs, the require-
ment of MyD88 in HSV-2–induced IFN-  secretion was
examined. MyD88 is an obligate adaptor molecule that in-
teracts with the intracellular domains of all known TLRs
and is necessary for subsequent signaling events. Although
MyD88 deficiency did not affect the phenotype or the fre-
quency of the bone marrow pDCs as determined by
FACS® (data not shown), MyD88 /  bone marrow cells
were not capable of secreting IFN-  in response to live or
inactivated HSV-2 (Fig. 2 A). In addition, sorted pDCs
from MyD88 /  mice were unable to secrete IFN-  in re-
sponse to HSV-2 (unpublished data), thereby demonstrat-
ing that a pure population of pDCs lacking MyD88 is also
unable to secrete IFN-  in response to HSV-2. The lack of
IFN-  secretion from MyD88 /  pDCs was specific to
HSV-2 and CpG, as the IFN-  response to Poly I:C by
MyD88 /  bone marrow was similar to that seen in wild-
type bone marrow (Fig. 2 A), presumably owing to the
MyD88-independent pathway for type I IFN secretion for
TLR3 (24, 25). Therefore, an intact MyD88-dependent
pathway is required for HSV-2–induced IFN-  secretion
from pDCs.
TLR9 Is Required for HSV-induced IFN-  Secretion from
pDCs. The finding that HSV-2–induced IFN-  secretion
depended on MyD88 led us to examine the specific role of
TLR9 in this process. TLR9 was chosen as a target of in-
vestigation because pDCs are known to express high levels
Figure 2. IFN-  secretion requires MyD88 and TLR9 signaling in
vitro and in vivo. (A) Bone marrow cells from wild-type or MyD88 / 
mice were cultured at 5   106 cells/ml for 18 h with either media alone,
CpG (5  g/ml) or live HSV-2 (5   106 PFU/ml), UV-HSV-2 (5   106
PFU/ml), or Poly I:C (25  g/ml) and IFN-  was measured by ELISA.
(B) IFN-  levels were measured from bone marrow cells harvested from
wild-type (B6 129F2), MyD88 / , TLR4 / , and TLR9 /  mice stimu-
lated for 18 h with media alone, CpG (5  g/ml), or UV-HSV-2 (5   106
PFU/ml) at 5   106 cells/ml. (C) Wild-type, MyD88 / , and TLR9 / 
mice received i.v. injections of 107 PFU of UV-HSV-2. 6 h after injec-
tion, serum was collected by cardiac puncture and measured for IFN- 
by ELISA. Results are representative of three independent experiments.T
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of TLR9 and the natural ligand for this receptor, CpG, is
found abundantly in HSV-2 genomic DNA (18). Using
real-time PCR, we observed that the sorted pDCs ex-
pressed TLR9 (unpublished data). To investigate this hy-
pothesis, the bone marrow cells of wild-type, MyD88 / ,
and TLR9 /  mice were stimulated in vitro with CpG or
UV-HSV-2. As a control, bone marrow cells from
TLR4 /  mice were also examined in parallel. Strikingly,
TLR9 /  cells were unable to secrete IFN-  in response
to HSV-2, whereas TLR4 /  or wild-type bone marrow
cells secreted similar high levels of IFN-  (Fig. 2 B). The
ability of the TLR4 /  bone marrow cells to secrete IFN- 
to HSV-2 at the normal levels eliminated the possibility
that LPS contamination accounted for the observed IFN- 
secretion by pDCs. These data clearly demonstrate the re-
quirement for TLR9 in HSV-2 recognition by pDCs, and
that this interaction is critical in the ability of pDCs to se-
crete IFN-  in response to HSV-2.
TLR9 Is Required for In Vivo HSV-2–mediated IFN-  Se-
cretion. In a previous study, pDCs were identified as the
primary source of IFN-  secretion after i.v. inoculation of
viruses including HSV-1 (26). Using a similar approach, we
examined the in vivo relevance of HSV-2 recognition by
TLR9 in IFN-  secretion. Mice were injected i.v. with ei-
ther PBS or 107 PFU of UV-HSV-2 and 6 h later, serum
was collected for measurement of IFN-  levels by ELISA.
Serum from wild-type mice injected with UV-HSV-2 was
found to contain significant levels of IFN- , whereas no
IFN-  was detected in the serum of MyD88 /  or
TLR9 /  mice injected with UV-HSV-2 (Fig. 2 C). Thus,
secretion of IFN-  upon in vivo inoculation of HSV-2 also
requires an intact TLR9 signaling pathway.
HSV-2 Genomic DNA Provides the Ligand for TLR9 Ex-
pressed by pDCs. Our data indicated that TLR9 is re-
quired for the HSV-mediated induction of IFN-  secre-
tion from pDCs. The only known ligand for TLR9 is the
unmethylated CpG motif, which is found in bacterial and
viral DNA. To examine whether CpG motifs within the
HSV-2 genome were responsible for binding TLR9 and
inducing IFN-  secretion, TLR9 signaling was specifically
blocked using an oligonucleotide containing the inhibitory
CpG motif (17). The activity of inhibitory CpG (iCpG;
CpG 2088) was first confirmed by coincubation with stim-
ulatory CpG (CpG 2084). As shown in Fig. 3 A, when
stimulatory CpG and 10 or 100 times that amount of iCpG
was used to treat bone marrow cells, IFN-  secretion was
completely diminished. Similarly, when iCpG was used
with HSV-2, there was a dose-dependent reduction in the
levels of IFN-  secreted that correlated with increasing the
amount of iCpG used (Fig. 3 B). The amount of iCpG
(100  g/ml) that was required to completely inhibit vir-
ion-mediated IFN-  secretion from pDCs was  120,000-
fold higher than the amount of CpG motifs present within
the added virions (see Materials and Methods for calcula-
tion). Thus, compared with the synthetic CpG oligonucle-
otide, the virion-associated DNA was 1,200 times more
difficult to inhibit with iCpG. The bone marrow cells of
the MyD88 /  and TLR9 /  mice failed to induce an
IFN-  response under the same conditions (Fig. 3 B).
Thus, these results suggested that CpG motifs present in the
HSV-2 genome are highly capable of activating TLR9 and
inducing IFN-  secretion from pDCs.
Finally, the viral ligand responsible for TLR9 activation
in pDCs was examined. First, stimulation with DNA iso-
lated from purified HSV-2 virions resulted in IFN-  secre-
tion from pDCs (Fig. 3 C). Roughly 600-fold higher
amounts of purified naked viral DNA was required to pro-
duce similar IFN-  secretion from pDCs stimulated with
5   106 PFU/ml of purified UV-inactivated virions (Fig.
3 C; see Materials and Methods for calculation). Digestion
of purified HSV-2 DNA by deoxyribonuclease (DNase)
completely diminished its ability to stimulate pDC secre-
tion of IFN-  (Fig. 3 C). This effect was not due to the
toxicity mediated by DNase since DNase treatment of
R848, a ligand for TLR7 that is not digested by DNase,
did not alter cytokine secretion from pDCs (unpublished
data). Thus, the genomic DNA of HSV-2 presented in the
virion-encapsulated form represents a potent activator of
TLR9 expressed by pDCs.
Figure 3. HSV-2 genomic DNA activates IFN-  secretion from pDCs
via TLR9. Bone marrow cells from wild-type, MyD88 / , and TLR9 / 
mice were stimulated with (A) stimulatory CpG alone (100 ng/ml) or
with 1  g/ml or 10  g/ml inhibitory CpG (iCpG) or (B) UV-HSV-2
(5   106 PFU/ml) with or without iCpG at 1  g/ml, 10  g/ml, or 100
 g/ml. Cells were cultured at 5   106 cells/ml with stimuli for 18 h and
IFN-  was measured by ELISA. (C) Bone marrow cells harvested from
B6 129F2 mice were cultured for 18 h in the presence of either 5   106
PFU/ml UV-HSV-2, purified HSV-2 DNA (547 ng/ml or 600  more
DNA than that present in 5   106 PFU/ml of virions) as well as 10-fold
dilutions (54.72 ng/ml or 60 , 5.42 ng/ml or 6 ), HSV-2 DNA (547
ng/ml) digested with DNase, or DNase alone. 18 h later, supernatants
were harvested and IFN-  levels were measured by ELISA.T
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Recognition of HSV-2 by TLR9 Requires an Intact Endocytic
Pathway. In an effort to understand the intracellular
mechanism of HSV-2 recognition by pDCs, we examined
the requirement for the endocytic pathway. As TLR9 must
be recruited to the lysosomal compartment upon synthetic
CpG oligonucleotide-driven stimulation (27), we hypothe-
sized that HSV-2 recognition also requires the maturation
of endosomal vesicles in order to activate the TLR9 path-
way. To test this hypothesis, bone marrow cells from wild-
type mice were first treated with inhibitors of acidification
of the endosomes, chloroquine or bafilomycin A1. These
inhibitors of endosomal acidification reduced HSV-2–
induced secretion of IFN-  from pDCs in a dose depen-
dent manner (Fig. 4, A and C). The reduction in IFN- 
secretion was not due to the toxicity of these reagents, as
IL-12p40 secretion from pDCs stimulated with R848, a
ligand for TLR7, was not affected by pretreatment with
these inhibitors (Fig. 4, B and D). Thus, HSV-2–mediated
activation of TLR9 also requires endocytosis and acidifica-
tion of endosomes within the pDCs.
Discussion
The TLRs have been shown to play a crucial role in the
innate recognition of microbial pathogens in mammals and
insects (3). Stimulation through the TLR molecules pro-
vides a vital signal for the activation of DCs and macro-
phages in response to bacterial and fungal stimuli including
zymosan (TLR2), lipopolysaccharide (TLR4), lipoteichoic
acid (TLR4), flagellin (TLR5), and unmethylated CpG
DNA (TLR9) (3). However, little is known with respect
to the role of TLRs in antiviral immunity in vivo. The
pDCs have been known for their exquisite ability to secrete
high levels of type I IFNs in response to virus infection.
Both the expression of TLR7 and TLR9, as well as the re-
sponsiveness to their respective ligands, have been docu-
mented in both human and mouse pDCs (7, 14, 28, 29).
Because the HSV-2 genome contains a high frequency of
CpG motifs (18), we hypothesized that TLR9 may be in-
volved in the recognition of HSV-2 by pDCs.
The signaling pathways of TLRs have been extensively
studied. All known TLRs have been shown to utilize the
MyD88 signaling pathway. The MyD88 adaptor protein
associates with the TLRs via interaction with the Toll/IL-1
receptor (TIR) domains. Upon stimulation, MyD88 re-
cruits a death domain–containing serine/threonine kinase,
the IL-1R–associated kinase (IRAK). Upon IRAK phos-
phorylation, it in turn associates with TRAF6, leading to
activation of two separate signaling pathways, JNK and
NF- B (3). Recently, MyD88-independent TLR signaling
events involving TIR domain-containing adaptor protein
(TIRAP) (30) and TIR domain-containing adaptor induc-
ing IFN-  (TRIF; reference 25) have been described.
However, our results demonstrated a complete dependency
for MyD88 and TLR9 in HSV-induced IFN-  secretion
from pDCs. Therefore, pDCs seem to possess a unique sig-
naling pathway whereby TLR9 recognition of HSV-2
DNA leads to MyD88 activation that ultimately results in
IFN-  secretion, which is not shared by other DC subsets.
Future studies are needed to examine the precise mecha-
nism by which MyD88-dependent downstream signaling
events result in the activation of the IFN-  promoter after
HSV-recognition by pDCs.
In this study, we have demonstrated that the pDCs from
mouse bone marrow secrete high levels of IFN-  in re-
sponse to HSV-2. Remarkably, this recognition does not
require virus replication and was blocked by the addition of
inhibitory CpG which specifically blocks the activation of
TLR9 (17) in a dose-dependent fashion. Further, pDCs
from MyD88 or TLR9 deficient mice, but not TLR4-
knockout mice, failed to secrete IFN- . The TLR9-medi-
ated recognition of HSV-2 required acidification of the
endosomes similar to that described for synthetic CpG oli-
gonucleotide (27). Finally, in vivo injection of HSV-2
resulted in serum IFN-  secretion only in mice that had
intact TLR9 signaling. Here, we propose a model by
which viral DNA is recognized by pDCs through TLR9.
We have demonstrated that virion-coated viral DNA is at
least 600 times more potent than linear naked viral DNA
or CpG synthetic oligonucleotide in inducing IFN-  se-
cretion from pDCs. The efficiency of virion-associated vi-
ral DNA in triggering TLR9 may be explained by two
mechanisms: (a) the virion associated DNA is resistant to
degradation by enzymatic digestion by DNase compared
with naked viral DNA or synthetic oligonucleotide con-
taining CpG motifs, and (b) the virion-encapsulated DNA
may be endocytosed much more efficiently than free DNA
in solution. A large body of evidence exists for efficient en-
docytosis of viruses involving caveolae-, clathrin-, non-
clathrin/noncaveolae-mediated endocytic mechanisms (for
a review, see reference 31). Collectively, these results pro-
Figure 4. Endosomal acidification is required for pDC activation by
HSV-2. Wild-type bone marrow cells were pretreated with either media
alone, chloroquine (A and B), or with bafilomycin A1 (C and D) at the
indicated concentrations. Either stimulatory CpG oligonucleotide (5  g/
ml), UV-HSV-2 (5   106 PFU/ml), or R848 (1  g/ml) were added to
the pretreated cells and incubated for 18 h at 37 C. Supernatants were
collected and IFN-  (A and C) or IL-12p40 (B and D) levels were mea-
sured using ELISA.T
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vide the first evidence that pDCs recognize CpG motifs
present in the genomic DNA of viruses via TLR9, and that
this recognition is required for IFN-  secretion by these
cells. The TLR9-mediated recognition of HSV implicates
the importance of this recognition pathway for other DNA
viruses by the pDCs.
We wish to thank Dr. Charles Dela Cruz for critical discussion. 
A. Iwasaki was supported by a Burroughs Wellcome Career
Award in Biomedical Sciences.
Submitted: 31 January 2003
Revised: 20 May 2003
Accepted: 6 June 2003
References
1. Cates, W., Jr. 1999. Estimates of the incidence and preva-
lence of sexually transmitted diseases in the United States.
American Social Health Association Panel. Sex. Transm. Dis.
26:S2–S7.
2. Zhao, X.Y., E. Deak, K. Soderberg, M. Linehan, D. Spez-
zano, J. Zhu, D.M. Knipe, and A. Iwasaki. 2003. Vaginal
submucosal dendritic cells, but not Langerhans’ cells, induce
protective Th1 responses to herpes simplex virus-2. J. Exp.
Med. 197:153–162.
3. Medzhitov, R. 2001. Toll-like receptors and innate immu-
nity. Nat. Rev. Immunol. 1:135–145.
4. Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N.
Yessaad, C. Dezutter-Dambuyant, A. Vicari, A. O’Garra, C.
Biron, F. Briere, and G. Trinchieri. 2001. Mouse type I IFN-
producing cells are immature APCs with plasmacytoid mor-
phology. Nat. Immunol. 2:1144–1150.
5. Brawand, P., D.R. Fitzpatrick, B.W. Greenfield, K. Brasel,
C.R. Maliszewski, and T. De Smedt. 2002. Murine plasma-
cytoid pre-dendritic cells generated from flt3 ligand-supple-
mented bone marrow cultures are immature APCs. J. Immu-
nol. 169:6711–6719.
6. Gilliet, M., A. Boonstra, C. Paturel, S. Antonenko, X.L. Xu,
G. Trinchieri, A. O’Garra, and Y.J. Liu. 2002. The develop-
ment of murine plasmacytoid dendritic cell precursors is dif-
ferentially regulated by FLT3-ligand and granulocyte/macro-
phage colony-stimulating factor. J. Exp. Med. 195:953–958.
7. Ito, T., R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K.
Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara.
2002. Interferon-alpha and interleukin-12 are induced differ-
entially by Toll-like receptor 7 ligands in human blood den-
dritic cell subsets. J. Exp. Med. 195:1507–1512.
8. Siegal, F.P., N. Kadowaki, M. Shodell, P.A. Fitzgerald-
Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y.J. Liu. 1999.
The nature of the principal type 1 interferon-producing cells
in human blood. Science. 284:1835–1837.
9. Nakano, H., M. Yanagita, and M.D. Gunn. 2001.
CD11c( )B220( )Gr-1( ) cells in mouse lymph nodes and
spleen display characteristics of plasmacytoid dendritic cells. J.
Exp. Med. 194:1171–1178.
10. O’Keeffe, M., H. Hochrein, D. Vremec, I. Caminschi, J.L.
Miller, E.M. Anders, L. Wu, M.H. Lahoud, S. Henri, B.
Scott, et al. 2002. Mouse plasmacytoid cells: long-lived cells,
heterogeneous in surface phenotype and function, that differ-
entiate into CD8( ) dendritic cells only after microbial stim-
ulus. J. Exp. Med. 196:1307–1319.
11. Dalod, M., T.P. Salazar-Mather, L. Malmgaard, C. Lewis, C.
Asselin-Paturel, F. Briere, G. Trinchieri, and C.A. Biron.
2002. Interferon alpha/beta and interleukin 12 responses to
viral infections: pathways regulating dendritic cell cytokine
expression in vivo. J. Exp. Med. 195:517–528.
12. Muller, U., U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic,
R.M. Zinkernagel, and M. Aguet. 1994. Functional role of
type I and type II interferons in antiviral defense. Science. 264:
1918–1921.
13. Katze, M.G., Y. He, and M. Gale, Jr. 2002. Viruses and in-
terferon: a fight for supremacy. Nat. Rev. Immunol. 2:675–
687.
14. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrs-
dorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quanti-
tative expression of toll-like receptor 1-10 mRNA in cellular
subsets of human peripheral blood mononuclear cells and
sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:
4531–4537.
15. Boonstra, A., C. Asselin-Paturel, M. Gilliet, C. Crain, G.
Trinchieri, Y.J. Liu, and A. O’Garra. 2003. Flexibility of
mouse classical and plasmacytoid-derived dendritic cells in di-
recting T helper type 1 and 2 cell development: dependency
on antigen dose and differential toll-like receptor ligation. J.
Exp. Med. 197:101–109.
16. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H.
Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda,
and S. Akira. 2000. A Toll-like receptor recognizes bacterial
DNA. Nature. 408:740–745.
17. Stunz, L.L., P. Lenert, D. Peckham, A.K. Yi, S. Haxhinasto,
M. Chang, A.M. Krieg, and R.F. Ashman. 2002. Inhibitory
oligonucleotides specifically block effects of stimulatory CpG
oligonucleotides in B cells. Eur. J. Immunol. 32:1212–1222.
18. Karlin, S., W. Doerfler, and L.R. Cardon. 1994. Why is
CpG suppressed in the genomes of virtually all small eukary-
otic viruses but not in those of large eukaryotic viruses? J. Vi-
rol. 68:2889–2897.
19. Zheng, M., D.M. Klinman, M. Gierynska, and B.T. Rouse.
2002. DNA containing CpG motifs induces angiogenesis.
Proc. Natl. Acad. Sci. USA. 99:8944–8949.
20. Jones, C.A., T.J. Taylor, and D.M. Knipe. 2000. Biological
properties of herpes simplex virus 2 replication-defective mu-
tant strains in a murine nasal infection model. Virology. 278:
137–150.
21. Eloranta, M.L., and G.V. Alm. 1999. Splenic marginal metal-
lophilic macrophages and marginal zone macrophages are the
major interferon-alpha/beta producers in mice upon intrave-
nous challenge with herpes simplex virus. Scand. J. Immunol.
49:391–394.
22. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsut-
sui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted
disruption of the MyD88 gene results in loss of IL-1- and IL-
18-mediated function. Immunity. 9:143–150.
23. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa,
Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge:
Toll-like receptor 4 (TLR4)-deficient mice are hyporespon-
sive to lipopolysaccharide: evidence for TLR4 as the Lps
gene product. J. Immunol. 162:3749–3752.
24. Oshiumi, H., M. Matsumoto, K. Funami, T. Akazawa, and
T. Seya. 2003. TICAM-1, an adaptor molecule that partici-
pates in Toll-like receptor 3-mediated interferon-beta induc-
tion. Nat. Immunol. 4:161–167.
25. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi,
K. Takeda, and S. Akira. 2002. Cutting edge: a novel Toll/T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
520 Toll-like Receptor 9–mediated Recognition of Herpes Simplex Virus-2
IL-1 receptor domain-containing adapter that preferentially
activates the IFN-beta promoter in the Toll-like receptor sig-
naling. J. Immunol. 169:6668–6672.
26. Barchet, W., M. Cella, B. Odermatt, C. Asselin-Paturel, M.
Colonna, and U. Kalinke. 2002. Virus-induced interferon al-
pha production by a dendritic cell subset in the absence of
feedback signaling in vivo. J. Exp. Med. 195:507–516.
27. Ahmad-Nejad, P., H. Hacker, M. Rutz, S. Bauer, R.M.
Vabulas, and H. Wagner. 2002. Bacterial CpG-DNA and li-
popolysaccharides activate Toll-like receptors at distinct cel-
lular compartments. Eur. J. Immunol. 32:1958–1968.
28. Gibson, S.J., J.M. Lindh, T.R. Riter, R.M. Gleason, L.M.
Rogers, A.E. Fuller, J.L. Oesterich, K.B. Gorden, X. Qiu,
S.W. McKane, et al. 2002. Plasmacytoid dendritic cells pro-
duce cytokines and mature in response to the TLR7 agonists,
imiquimod and resiquimod. Cell. Immunol. 218:74–86.
29. Jarrossay, D., G. Napolitani, M. Colonna, F. Sallusto, and A.
Lanzavecchia. 2001. Specialization and complementarity in
microbial molecule recognition by human myeloid and plas-
macytoid dendritic cells. Eur. J. Immunol. 31:3388–3393.
30. Horng, T., G.M. Barton, and R. Medzhitov. 2001. TIRAP:
an adapter molecule in the Toll signaling pathway. Nat. Im-
munol. 2:835–841.
31. Sieczkarski, S.B., and G.R. Whittaker. 2002. Dissecting virus
entry via endocytosis. J. Gen. Virol. 83:1535–1545.